Teva’s BXCL501 Is Under FDA Review for At-Home Use
The FDA is reviewing BXCL501, a dexmedetomidine sublingual film, for first-ever at-home use to treat agitation associated with schizophrenia or bipolar I or II disorder in adults.
The FDA is reviewing BXCL501, a dexmedetomidine sublingual film, for first-ever at-home use to treat agitation associated with schizophrenia or bipolar I or II disorder in adults.